The World Health Organization has predicted that by 2050, there would be one person in the group of 85 across the globe to be afflicted with Alzheimer's disease. In most developed countries, it is the fourth leading cause of death.

Many researchers were being conducted to devise a treatment for this disease which robs away the unique memories of our closed ones. But a ray of hope has been seen with the Salk Institute for Biological Studies research, which got published in the journal PLoS ONE.

Researchers were of the view that their Alzheimer's drug, known as J147, has proved to be effective by preventing loss of memory and has also helped to retain good memory. Previous researches have focused on to establish a relationship between amyloid plaques and neurofibrillary tangles in the brain. But the Salk team did not opt for a traditional route and took a new approach for its mice test.

They used living neurons which were grown in laboratory dishes to check its efficacy to protect the brain cells from different pathogens which are involved with brain ageing. They found that they need to alter the product so it could be more effective. For which, they altered the chemical structure, said lead researcher Marguerite Prior.

Prior it was explained, about the reason for taking all together a different road, "In contrast, by testing these compounds in living cell cultures, we can determine what they do against a range of age-related problems and select the best candidate that addresses multiple aspects of the disease, not just one”.

He further affirmed that their product has shown improvement in retaining memory not only in Alzheimer's mice but also in normal mice. It also helps the brain from the loss of synaptic connections. Till now, no drug has been developed which targets both the things.